{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T10:33:17Z","timestamp":1781951597844,"version":"3.54.5"},"reference-count":26,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","cghjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.cgh.2015.05.039","type":"journal-article","created":{"date-parts":[[2015,6,14]],"date-time":"2015-06-14T06:26:26Z","timestamp":1434263186000},"page":"2353-2359.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Lanreotide Reduces Liver Volume, But Might Not Improve Muscle Wasting or Weight Loss, in Patients With Symptomatic Polycystic Liver Disease"],"prefix":"10.1016","volume":"13","author":[{"given":"Frederik","family":"Temmerman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thien Ahn","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ragna","family":"Vanslembrouck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Coudyzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaak","family":"Billen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Dobbels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos","family":"van Pelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bert","family":"Bammens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Pirson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Nevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2015.05.039_bib1","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/j.1365-2036.2011.04783.x","article-title":"Systematic review: the pathophysiology and management of polycystic liver disease","volume":"34","author":"Temmerman","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2015.05.039_bib2","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1478-3231.2010.02247.x","article-title":"Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases","volume":"31","author":"Van Keimpema","year":"2011","journal-title":"Liver Int"},{"key":"10.1016\/j.cgh.2015.05.039_bib3","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/SLA.0b013e3181ad83dc","article-title":"Polycystic liver disease: a critical appraisal of hepatic resection, cyst fenestration, and liver transplantation","volume":"250","author":"Schnelldorfer","year":"2009","journal-title":"Ann Surg"},{"key":"10.1016\/j.cgh.2015.05.039_bib4","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1053\/jlts.2001.22178","article-title":"Liver transplantation for polycystic liver disease","volume":"7","author":"Pirenne","year":"2001","journal-title":"Liver Transpl"},{"key":"10.1016\/j.cgh.2015.05.039_bib5","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1432-2277.2011.01360.x","article-title":"Excellent survival after liver transplantation for isolated polycystic liver disease: an European Liver Transplant Registry study","volume":"24","author":"van Keimpema","year":"2011","journal-title":"Transpl Int"},{"key":"10.1016\/j.cgh.2015.05.039_bib6","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1172\/JCI39375","article-title":"Acromegaly pathogenesis and treatment","volume":"119","author":"Melmed","year":"2009","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.cgh.2015.05.039_bib7","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/annonc\/mdh216","article-title":"Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system","volume":"15","author":"Oberg","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cgh.2015.05.039_bib8","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2036.2009.04174.x","article-title":"Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours","volume":"31","author":"Modlin","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2015.05.039_bib9","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1053\/j.gastro.2006.12.039","article-title":"Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3\u2032,5\u2032-cyclic monophosphate","volume":"132","author":"Masyuk","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2015.05.039_bib10","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1053\/j.gastro.2009.07.052","article-title":"Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial","volume":"137","author":"van Keimpema","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2015.05.039_bib11","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1681\/ASN.2009121291","article-title":"Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease","volume":"21","author":"Hogan","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.cgh.2015.05.039_bib12","doi-asserted-by":"crossref","first-page":"783","DOI":"10.2215\/CJN.05380709","article-title":"Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide","volume":"5","author":"Caroli","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.cgh.2015.05.039_bib13","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1365-2036.2011.04923.x","article-title":"The long-term outcome of patients with polycystic liver disease treated with lanreotide","volume":"35","author":"Chrispijn","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2015.05.039_bib14","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2036.2011.04693.x","article-title":"Long-term results of treatment of malignant carcinoid syndrome with prolonged release lanreotide (Somatuline Autogel)","volume":"34","author":"Khan","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2015.05.039_bib15","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/apt.12384","article-title":"Safety and efficacy of different lanreotide doses in the treatment of polycystic liver disease: pooled analysis of individual patient data","volume":"38","author":"Temmerman","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2015.05.039_bib16","unstructured":"http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/022074s006lbl.pdf"},{"key":"10.1016\/j.cgh.2015.05.039_bib17","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/jhep.2003.50006","article-title":"Clinical profile of autosomal dominant polycystic liver disease","volume":"37","author":"Qian","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2015.05.039_bib18","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.jhep.2014.06.024","article-title":"Development and validation of a polycystic liver disease-complaint-specific-assessment (POLCA)","volume":"61","author":"Temmerman","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2015.05.039_bib19","unstructured":"Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, version 3.0. DCTD, NCI, NIH, DHHS March 31, 2003 (available: http:\/\/ctep.cancer.gov), publish date: August 9,\u00a02006."},{"key":"10.1016\/j.cgh.2015.05.039_bib20","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1136\/ard.61.12.1117","article-title":"Probable adverse effects of long term use of somatostatin analogues in patients with RA","volume":"61","author":"Marcora","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cgh.2015.05.039_bib21","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0079-6123(10)82011-4","article-title":"Somatostatin and somatostatin receptors: from basic concepts to clinical applications","volume":"182","author":"De Martino","year":"2010","journal-title":"Prog Brain Res"},{"key":"10.1016\/j.cgh.2015.05.039_bib22","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1002\/lt.20974","article-title":"Model for end-stage liver disease (MELD) exception for polycystic liver disease","volume":"12","author":"Arrazola","year":"2006","journal-title":"Liver Transpl"},{"key":"10.1016\/j.cgh.2015.05.039_bib23","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1152\/japplphysiol.00744.2004","article-title":"Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image","volume":"97","author":"Shen","year":"2004","journal-title":"J\u00a0Appl Physiol"},{"key":"10.1016\/j.cgh.2015.05.039_bib24","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1158\/1078-0432.CCR-08-2242","article-title":"Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment","volume":"15","author":"Prado","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cgh.2015.05.039_bib25","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1093\/ndt\/gfs152","article-title":"Somatostatin analog therapy for severe polycystic liver disease: results after 2 years","volume":"27","author":"Hogan","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.cgh.2015.05.039_bib26","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1210\/jc.2003-030412","article-title":"Evaluation of diagnostic accuracy of insulin-like growth factor (IGF)-I and IGF-binding protein-3 in growth hormone-deficient children and adults using ROC plot analysis","volume":"88","author":"Boquete","year":"2003","journal-title":"J\u00a0Clin Endocrinol Metab"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356515007892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356515007892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T15:06:13Z","timestamp":1748012773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356515007892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":26,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S1542356515007892"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2015.05.039","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lanreotide Reduces Liver Volume, But Might Not Improve Muscle Wasting or Weight Loss, in Patients With Symptomatic Polycystic Liver Disease","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2015.05.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 AGA Institute. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}